These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37899506)

  • 1. Clozapine augmentation with long-acting antipsychotic injections: A case series and systematic review.
    Oloyede E; Dima A; Taylor D; Cheung H; Dzahini O; Shergill S; Whiskey E
    Acta Psychiatr Scand; 2023 Dec; 148(6):538-552. PubMed ID: 37899506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study.
    Bioque M; Parellada E; García-Rizo C; Amoretti S; Fortea A; Oriolo G; Palau P; Boix-Quintana E; Safont G; Bernardo M
    Eur Psychiatry; 2020 Jul; 63(1):e71. PubMed ID: 32669145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.
    Gentile S
    Pharmacotherapy; 2013 Oct; 33(10):1087-106. PubMed ID: 23776129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K; Pan X; Wang R; Yang E; Benson C
    Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical pharmacokinetics and pharmaceutical forms of long-acting injectable antipsychotics].
    Kyziridis TC
    Psychiatriki; 2022 Jun; 33(2):139-148. PubMed ID: 34390562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials.
    Wang D; Schneider-Thoma J; Siafis S; Burschinski A; Dong S; Wu H; Zhu Y; Davis JM; Priller J; Leucht S
    Schizophr Bull; 2024 Jan; 50(1):132-144. PubMed ID: 37350486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).
    Novakovic V; Adel T; Peselow E; Lindenmayer JP
    Clin Neuropharmacol; 2013; 36(2):59-62. PubMed ID: 23503549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.
    Takekita Y; Koshikawa Y; Fabbri C; Sakai S; Sunada N; Onohara A; Nishida K; Yoshimura M; Kato M; Serretti A; Kinoshita T
    BMC Psychiatry; 2016 May; 16():172. PubMed ID: 27236412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.
    Kishimoto T; Hagi K; Kurokawa S; Kane JM; Correll CU
    Lancet Psychiatry; 2021 May; 8(5):387-404. PubMed ID: 33862018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
    Patel R; Chesney E; Taylor M; Taylor D; McGuire P
    Psychol Med; 2018 Jul; 48(10):1616-1623. PubMed ID: 29039277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders.
    Boyer L; Falissard B; Nuss P; Collin C; Duret S; Rabbani M; De Chefdebien I; Tonelli I; Llorca PM; Fond G
    Mol Psychiatry; 2023 Sep; 28(9):3709-3716. PubMed ID: 37479781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia.
    Joshi K; Mao L; Biondi DM; Millet R
    BMC Psychiatry; 2018 Jan; 18(1):24. PubMed ID: 29378547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan.
    Okada Y; Inada K; Akazawa M
    Schizophr Res; 2023 Feb; 252():300-308. PubMed ID: 36706475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.